Skip to main content
. 2012 Sep 6;7(9):e44707. doi: 10.1371/journal.pone.0044707

Figure 1. Identification and characterization of a novel NY-ESO-1 TCD8+ epitope.

Figure 1

A. PBMCs were collected from patient 8 on day 70 following vaccination with NY-ESO-1 ISCOMATRIX™ vaccine. These cells were cultured with a panel of overlapping NY-ESO-1 18 mer peptides and then tested for responsiveness to each peptide in an ICS assay for IFN-γ. Because the background to control peptides was negligible, the results from individual cultures were plotted as a single combined figure. B, C, TCD8+ line expanded with NY-ESO-179–96 18 mer was tested under FCS-free condition for its reactivity to various HPLC-purified peptides (B) and the minimum peptide NY-ESO-188–96 at various peptide concentrations (C). D, a panel of LCL lines sharing HLA alleles with patient 8 were pulsed with the minimum NY-ESO-188–96 peptide, extensively washed, co-cultured with NY-ESO-188–96-specific TCD8+ line and followed with ICS.